ClinVar Miner

Submissions for variant NM_001374504.1(TMPRSS6):c.836+1G>A

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV003226028 SCV003922100 uncertain significance Iron-refractory iron deficiency anemia 2023-05-02 criteria provided, single submitter curation The heterozygous c.836+1G>A variant in TMPRSS6 was identified by our study in one individual with iron deficiency anemia. The c.836+1G>A variant in TMPRSS6 has been previously reported in one individual with iron-refractory iron deficiency anemia (Heeney et al., Blood 2009; 114 (22)) but has been identified in 0.003% (1/29098) of South Aisan chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs757356137). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. A different nucleotide change that also results in a splice donor variant at the same site, c.863‚Äâ+‚Äâ1G>T, has been previously reported pathogenic (PMID: 27643674, PMID: 21618415), and the variant being assessed here, c.836+1G>A, is predicted by SpliceAI to have a similar effect on splicing. This variant is located in the 5' splice region. Computational tools predict a splicing impact, though this information is not predictive enough to determine pathogenicity. There is an in-frame cryptic splice site 42 bases from the intron-exon boundary, providing evidence that this variant may delete 14 amino acids instead of causing loss of function. However, this information is not predictive enough to determine pathogenicity. Loss of function of the TMPRSS6 gene is an established disease mechanism in autosomal recessive vasculitis, iron-refractory iron deficiency anemia. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PVS1_Moderate, PM2_Supporting, PS1_Supporting (Richards 2015).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.